Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 201

Results For "India"

3235 News Found

IMPCL registers impressive threefold increase in profit for FY21-22
News | November 11, 2022

IMPCL registers impressive threefold increase in profit for FY21-22

The dividend cheque of Rs. 9.93 crore for the Ministry of Ayush was handed over to Sonowal


ASG Eye Hospitals enters Haryana and expands footprint in UP
Healthcare | November 10, 2022

ASG Eye Hospitals enters Haryana and expands footprint in UP

ASG is accelerating its doctor-led mission to enhance the quality of care, deliver eye care for all, and improve quality of life across India.


Lupin Q2 FY2023 revenue remains flat
News | November 10, 2022

Lupin Q2 FY2023 revenue remains flat

Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.


Zydus receives USFDA approval for Bisoprolol Fumarate and Hydrochlorothiazide Tablets
Drug Approval | November 09, 2022

Zydus receives USFDA approval for Bisoprolol Fumarate and Hydrochlorothiazide Tablets

The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India


Lupin receives tentative approval from USFDA for Doxycycline Capsules
Drug Approval | November 09, 2022

Lupin receives tentative approval from USFDA for Doxycycline Capsules

Doxycycline Capsules (RLD Oracea) had estimated annual sales of US $215 million in the US


SeQuent Scientific to acquire 100% stake in Tineta Pharma
News | November 08, 2022

SeQuent Scientific to acquire 100% stake in Tineta Pharma

The acquisition is for an enterprise value of Rs. 218 crores


Balaxi Pharmaceuticals delivers strong growth in Q2 FY23
News | November 07, 2022

Balaxi Pharmaceuticals delivers strong growth in Q2 FY23

Revenue is up 23% whereas Profit After Tax expands 29% for the company


Lupin receives tentative approval from USFDA for Drospirenone Tablets
Drug Approval | November 07, 2022

Lupin receives tentative approval from USFDA for Drospirenone Tablets

Drospirenone Tablets (RLD Slynd) had estimated annual sales of US $141 million in the US


Rossari Biotech Q2 FY23 revenue up 11%; Profit down 9%
News | November 07, 2022

Rossari Biotech Q2 FY23 revenue up 11%; Profit down 9%

H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY